StocksMedium•29 September 2026•
1 min read
Amgen Reports Positive Phase 3 Results for Sjogren's Disease Treatment
Key Facts
1Amgen reported positive topline results from its pivotal dazodalibep study for adults with moderate-to-severe systemic Sjogren's disease.
2The study showed significant improvement on the ESSDAI endpoint, strengthening Amgen's autoimmune portfolio acquired from Horizon Therapeutics.
Amgen reported positive topline results from its pivotal dazodalibep study for adults with moderate-to-severe systemic Sjogren's disease. Kalkine Media reported that the study showed significant improvement on the ESSDAI endpoint, meeting its primary objective for patients with high disease activity.
The results strengthen Amgen's autoimmune portfolio, which includes assets acquired from Horizon Therapeutics, by addressing a condition with no currently approved therapies for its underlying biology. AMGN closed at $418.13 on September 28, 2026, having traded between a day high of $419.02 and a low of $410.96 during that session.